Overview

Initial Treatment of Patients With Immune Thrombocytopenic Purpura

Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study will compare treatment with 3 courses of high-dose dexamethasone versus treatment with prednisone, for patients recently diagnosed with immune thrombocytopenic purpura (ITP). The primary hypothesis is that patients treated with high-dose dexamethasone will obtain a more durable remission than patients treated with prednisone.
Phase:
Phase 3
Details
Lead Sponsor:
HealthCore-NERI
New England Research Institutes
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Prednisone